Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.

World journal of gastroenterology - 28 Dec 2016

Ghiringhelli Francois, Richard Corentin, Chevrier Sandy, Végran Frédérique, Boidot Romain

Abstract excerpt

Precision medicine is defined by the administration of drugs based on the tumor's particular genetic characteristics. It is developing quickly in the field of cancer therapy. For example, KRAS, NRAS and BRAF genetic testing demonstrates its efficiency for precision medicine in colorectal cancer (CRC). Besides for these well-known mutations, the purpose of performing larger genetic testing in this pathology is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Abdominal Pain
Share to Carcinoembryonic Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Hemorrhage

Share to Peripheral Nervous System Diseases

Share to Phthalazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Rectum

Share to Tumor Suppressor p53-Binding Protein 1

Source

Open in PubMed Open full text

Identifiers

PMID: 28082821
DOI: 10.3748/wjg.v22.i48.10680
PMCID: PMC5192280

Genes

BRAF
KRAS
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.PMID 28082821Read ↗

Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity.Semantic proximity Read ↗

Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP InhibitorsSemantic proximity Read ↗

Exploiting DNA repair defects in colorectal cancerSemantic proximity Read ↗

Chemotherapeutic agents for colorectal cancer with a defective mismatch repair system: The state of the artSemantic proximity Read ↗

PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reportsSemantic proximity Read ↗

Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic ImplicationsSemantic proximity Read ↗

Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target.Semantic proximity Read ↗

A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.Semantic proximity Read ↗

Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal CancerSemantic proximity Read ↗

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.Semantic proximity Read ↗

Base excision repair imbalance in colorectal cancer has prognostic value and modulates response to chemotherapySemantic proximity Read ↗

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.